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Diabetes Care for Patients with Peripheral
Arterial Disease
M. Heikkinen,1* M. Salmenpera¨,2 A. Lepa¨ntalo3 and M. Lepa¨ntalo1
Departments of 1Vascular Surgery, 2Anesthesiology, and 3Division of Hematology,
Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
The number of diabetics will increase almost 70% in developed countries during the next 20 years: peripheral arterial
disease is a common and costly complication. The incidence of cardiovascular disease (mortality and morbidity) due to ath-
erosclerosis, is higher among patients with diabetes than in those without diabetes. Intensive management of diabetes,
including glycaemic control, treatment of hypertension and dyslipidemia, as well as nonpharmacological interventions,
decreases both micro- and macrovascular complications. Aspirin and clopidogrel have less antiplatelet effect in patients
with diabetes. Metformin therapy is considered a risk factor for lactic acidosis if not withdrawn 2 days before angiography,
but this risk is extremely low in patients with normal renal function. Peri-operative hyperglycaemia and large fluctuations in
plasma glucose increase postoperative mortality and morbidity and careful measures are required to minimise these effects.
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The global prevalence of diabetes mellitus has in-
creased continuously and it has been predicted that
the number of adult diabetics will double within 30
years. Almost 250 million people, nearly 6% of adults
in the world, have diabetes.1 Patients with diabetes
have an average reduction in life expectancy of 5e10
years, mainly because of premature cardiovascular
disease (CVD).2 In Finland, 90% of the total health
care costs of diabetes are due to the complications of
the disease. The treatment of type II diabetes alone
cost 370V per person annually, but the cost of compli-
cations increases this to 8900V per person.2,3 The onset
of complications reduces the quality of life, particu-
larly when both microvascular and macrovascular
disease are present.4,5 Multiple modifiable risk factors,
including hyperglycaemia, hypertension, and dyslipi-
demia, increase the risk of poor outcome.6,7
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Excess mortality from cardiovascular disease (CVD)
compared to general population can be seen in all
age groups, especially in young people with type 1
diabetes. Macrovascular disease, which usually is dif-
fuse and distal affecting many vessels, is the main
cause of death in type 1 and type 2 diabetes.6 The
prevalence and mortality from all forms of CVD is
2e8 fold higher in the presence of diabetes.6,7 Dia-
betes increases the risk of asymptomatic peripheral
arterial disease (PAD) (Odds Ratio (OR) 3.8).8,9 The
Epidemiology of Diabetes Interventions and Compli-
cations study compared carotid intima-media thick-
ness in subjects with and without diabetes: after 6
years, intima-media thickness was greater in those
with diabetes.10 During an 11-year follow-up study,
almost a quarter (31/131) patients with type 2 dia-
betes, aged at 58 at entry, developed PAD during
follow-up and 21/29 deaths were attributed to CVD.11
In patients with diabetes, for every 1% increase in
hemoglobin A1c (HbA1c) there is a corresponding
26e28% increase risk of PAD.12 Insulin resistance iserved.
584 M. Heikkinen et al.a risk factor for PAD even in subjects without diabe-
tes, increasing the risk by about 50%.13
About half of all lower extremity amputations
are related to diabetes.9,14 Although the majority of
diabetic ulcers are neuropathic, almost 60% also
have an ischaemic component, with 10% being solely
ischaemic.15 Atherosclerosis is probably present in all
patients with long-duration diabetes.16 In critical
limb ischemia (CLI), PAD impairs blood flow so
that the nutritive requirements of the tissue cannot
be met.9 This is usually caused by multilevel arterial
occlusive disease.9 Patients with diabetes comprise
45e70% of those undergoing bypass surgery for
CLI.14,17,18
Improving Outcome by Treatment of Diabetes
The metabolic and haemodynamic abnormalities of
diabetes both contribute to the development of com-
plications. Microvascular complications are strongly
associated with CVD. The primary defect in PAD is
atherothrombotic occlusion of large vessels and
microangiopathy is not seen as a primary factor in
the development of tissue ischemia in patients with
diabetes. However, microvascular dysfunction can
be observed in the skin, which could render this organ
more susceptible to a reduction in perfusion pres-
sure.19 In addition, diabetic neuropathy, in both type
1 and 2 diabetic patients, results in increased shunting
of blood flow and an impaired inflammatory response
to various stimuli.20 Endothelial function, which is
impaired by most cardiovascular risk factors, eg
hypercholesterolemia, smoking appears to be a useful
marker of diabetic control.21 Recent reports indicate
that an improved metabolic control in diabetes, what-
ever the treatment used, is associated with near nor-
malization or restoration of normal endothelial
function.22
In both type 1 and type 2 diabetes, the lower the
glycated haemoglobin achieved the lower the risk
of microvascular complications.23e25 In Diabetes
Control and Complication Trial (DCCT), conven-
tional therapy of type 1 diabetes consisted of 1e2
insulin injections per day. Intensive therapy aimed
to achieve blood glucose values as close to the nor-
mal range as possible with 3 or more daily insulin
injections or with insulin pump.23 During the mean
follow-up of 6.5 years, patients in the intensively
treated group had significantly less microvascular
complications, nephropathy and retinopathy. When
major cardiovascular events and peripheral vascular
events were combined, intensive therapy reduced
the risk of macrovascular disease by 41%, althoughEur J Vasc Endovasc Surg Vol 33, May 2007this was not statistically significant. The prevalence
and amount of arterial calcification, 7e9 years after
the trial, were significantly lower in the intensive
treatment group compared with the conventional
therapy group despite, even though there was no
difference in HbA1c between the groups at late
follow-up.26 However mean HbA1c level during the
study period was significantly lower in the intensive
treatment group.
In the UK Prospective Diabetes Study (UKPDS), the
relation between exposure to glycaemia over time and
the risk of macrovascular or microvascular complica-
tions in patients with type 2 diabetes were determined
in 3600 patients. Each 1% reduction in updated mean
HbA1c was associated with reductions in risk of 21%
for any end point related to diabetes (P< 0.0001), 21%
for deaths related to diabetes (P< 0.0001), 14% for
myocardial infarction (P< 0.0001), and 37% for micro-
vascular complications (P< 0.0001). The lowest risk
was in those with HbA1c values in the normal range
(<6.0%).27
Current evidence suggests best therapy for diabe-
tes is associated with the targets in Table 1. If the vas-
cular surgeon identifies that these targets are not
being met or approached a patient with diabetes,
the diabetologists should be requested to optimise
therapy for the patient.
Table 1. Hemoglobin A1c (HbA1c), cholesterol, blood pressure
targets and other important factors for patients with DM to pre-
vent or slow cardiovascular disease
HbA1c (%) 6.5 mmol/l
Fasting <6.0 mmol/l
Post-prandial
(peak)
Individuals with type 1 diabetes
<7.5 mmol/l
Individuals with type 2 diabetes
7.5e9.0 mmol/l
Cholesterol LDL: Individuals without CVD <2.6 mmol/l
Individuals with CVD <1.8 mmol/l
Triglycerides<1.7 mmol/l
HDL: Men >1.0 mmol/l1.0 mmol/l
Women>1.2 mmol/l
Blood pressure Systolic blood pressure <130 mmHg
Diastolic blood pressure < 80 mmHg
Other important
factors
Aspirin therapy
Smoking cessation
Regular physical exercise (>35e45 min/day)
Weight control
Dietary habits
These goals are for patients in general and have to be adjusted for
an individual patient taking all aspects in consideration, for exam-
ple age (very young children or older adults may need modifica-
tions), history of severe hypoglycemia (HbA1c recommendation
higher), renal impairment, limited life expectancy and other comor-
bid conditions.
Modified from the European Guidelines for Cardiovascular disease
prevention and American Diabetes Association, Standards of med-
ical cari in diabetes 2007.70,71
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Smoking
Smoking cessation is a particular advantage to
patients with diabetes and peripheral arterial dis-
ease. The highest relative risk associated with PAD
is current smoking of 25 or more cigarettes daily
(OR¼ 7.3, 95% confidence interval (CI) 4.2e12.8).21
Both hyperglycemia and smoking can result in the
formation of advanced glycation end products and
in enhanced oxidative stress within the vessel wall,
suggesting that these process might play a central
role the development or progression of PAD.28 Diabe-
tes combined with smoking has high positive predic-
tive value for asymptomatic PAD (15%), when both
are lacking, rates for predicting asymptomatic PAD
is low (1%).8 The weight of evidence also suggests
that smoking adversely influences the success of
bypass surgery.
Blood pressure
By the age of 45 about 40% of patients with type 2
diabetes are hypertensive, the proportion increasing
to 60% by the age of 75.29 This combination provides
additive increases in the risk of major cardiovascular
events. Aggressive blood pressure control may be
the most important factor in preventing major cardio-
vascular events in patients with type 2 diabetes.30e32
In a Cochrane review, a reduction in systolic blood
pressure of 10 mmHg was associated with a 13% re-
duction in risk of microvascular events and an 11%
reduction for myocardial infarction.30 In the Multiple
Risk Factor Intervention Trial Diabetic Cohort, cardio-
vascular mortality was increased by 2e4 fold and the
association between systolic blood pressure and com-
plications had no threshold value.31 In UKPDS, reduc-
tions in risk in the group assigned to tight blood
pressure control (achieved 144/82) compared with
the group assigned to less tight blood pressure control
(achieved 154/87) were significant, reductions of 32%
in deaths related to diabetes ( p¼ 0.019), 44% in
strokes ( p¼ 0.013) and 37% in microvascular end-
points ( p¼ 0.0092) after mean follow-up of 8.4
years.32 Since diabetes is an important cardiovascular
risk factor, a lower target value for those with diabetes
(130/85 mmHg) than for others (140/90 mmHg) has
been proposed.33 All classes of antihypertensive
agents are effective in reducing blood pressure in
diabetes, with evidence of a concomitant reduction
in cardiovascular risk. Hypertensive patients have
a significantly increased risk for development oftype 2 diabetes, which is dependent on the class of
anti-hypertensive drug used. Diuretics and beta-
blockers have a prodiabetic effect, but angiotensin-
converting enzyme inhibitors and angiotensin II
receptor blockers may prevent diabetes more effec-
tively than the metabolically neutral calcium channel
blockers.
Dyslipidaemia
The metabolic abnormalities that cluster in patients
with type 2 diabetes and the metabolic syndrome
are all independent risk factors for atherogenesis
and dyslipidemia is an important, modifiable risk fac-
tor for CVD. Two placebo-controlled trials have
shown, that treatment with statins reduces the risk
of a major cardiovascular event by 37% in patients
with type 2 diabetes without clinically apparent
CVD.34,35 In a meta-analysis of randomized controlled
trials, lipid lowering drug treatment was at least as
effective in diabetic patients as in non-diabetic
patients.36 For primary prevention, the risk reduction
for major coronary events was 21% (95% CI 11%e30%)
and 23% (12%e33%) in patients with and without
diabetes respectively. For secondary prevention, the
corresponding risk reductions were 21% (10%e31%)
and 23% (19%e26%). All those aged 40 years with
diabetes and younger patients with diabetes at parti-
cularly high risk (microvascular or macrovascular
complications, hypertension, metabolic syndrome or
a strong family history for CVD) should be offered
statins.
Foot Care
Neuropathy with subsequent loss of protective sensa-
tions, muscular weakness and structural deformity as
well as autosympathectomy is the main cause for di-
abetic foot ulceration. Ischaemia alone is the cause
only in 10%,15 whereas inadequate tissue often perfu-
sion prevents healing. Neuropathy causes reulcera-
tion in case of inappropriate offloading. Therefore
continuous education of patients regarding skin
care, foot hygiene, off-loading, and proper footwear
is crucial to reducing the risk of an injury that can
lead to ulceration. A careful foot examination that
tests for neuropathy and arterial insufficiency can
identify legs at risk and should be a routine to the
diabetic patient. If foot ulcer has not shown any evi-
dence for healing in two weeks, careful examination
of the lower limb circulation with subsequent vascu-
lar reconstruction as appropriate is indicated. These
measures decreased first amputations in FinlandEur J Vasc Endovasc Surg Vol 33, May 2007
586 M. Heikkinen et al.1988e2002 from 924 to 387 per 100000 patients with
diabetes.37
Life-style Interventions
Type 2 diabetes is increasingly common, primarily be-
cause of increases in the prevalence of a sedentary
lifestyle and obesity. In about half of patients with
recently diagnosed type 2 diabetes, life-style inter-
ventions such as weight reduction and increased
physical activity may reverse the diabetes.38,39 In the
Finnish Diabetes Prevention Study (FDPS), 522 middle-
aged, overweight subjects with impaired glucose
tolerance were randomly assigned to either the inter-
vention group or the control group. Each subject in
the intervention group received individualized coun-
selling aimed at reducing weight, total intake of fat,
and intake of saturated fat and increasing intake of
fibre and physical activity.39 The cumulative incidence
of diabetes after four years was 11% (95% CI 6%e15%)
in the intervention group and 23% (17%e29%) in the
control group, a 58% risk reduction in the intervention
group (P< 0.001). After a median of 4 years of active
intervention period, participants who were still free
of diabetes were further followed up for a median
of 3 years, with median total follow-up of 7 years.
Beneficial lifestyle changes achieved in the interven-
tion group were maintained after the discontinuation
of the intervention, and the corresponding incidence
rates of diabetes during the post-intervention follow-
up were 4.6 and 7.2 ( p¼ 0.0401), indicating 36%
reduction in relative risk.40
Life-style intervention should be the initial man-
agement of newly diagnosed diabetic type 2 patients.
Since almost half of all those with type 2 diabetes are
not diagnosed it seems necessary to improve early
diagnoses of the disease.38,39
Antiplatelet Therapy
Aspirin (acetylsalicylic acid, ASA), which is recom-
mended for primary and secondary prevention in
patients with PAD, has been shown to have lower
antiplatelet activity in those with diabetes.41,42 The
reduced response of platelets from diabetic subjects
to aspirin is associated with a higher level of
HbA1c, lower concentration of HDL-cholesterol and
a higher total cholesterol concentration.41,42 Increased
platelet activity and decreased sensitivity to aspirin
have also been reported in patients with dyslipide-
mia, and one suggestion is that metabolic differences
in diabetics and metabolic syndrome might be theEur J Vasc Endovasc Surg Vol 33, May 2007reason to decreased aspirin efficacy in diabetics.43
There are several other mechansisms thay may
contribute to the diminished anti-platelet activity of
aspirin in diabetes.44,45 In addition the normal anti-
platelet activity of insulin has been reported to be
abolished in patients with diabetes or insulin-resistance
patients.46 Therefore, in the presence of diabetes higher
doses of aspirin have been proposed.44 However, there
is no studies on the possible optimal aspirin dose to
the diabetics.
Patients with diabetes also seem to benefit less
from clopidogrel, shown by objective measures of
platelet activation.47e49 Lepa¨ntalo et al. studied the
efficacy of a loading dose (300 mg) of clopidogrel in
patients undegoing elective percutaneous coronary
intervention.50 In patients with poor long-term glu-
cose balance (HbA1c) and elevated insulin C-peptide,
the clopidogrel-induced inhibition of platelet aggrega-
tion was significantly less than in normoglycaemic pa-
tients. Also, the patients with limited response to
clopidogrel (change in aggregation <10%) had higher
serum C-peptide levels than patients who responded
well to clopidogrel.50 The reasons for these differences
are unknown.
Metformin Therapy
The biguanide metformin (dimethylbiguanide) is an
oral anti-hyperglycemic drug used in non-insulin de-
pendent diabetes. TheUKPDS indicated thatmetformin
treatment was associated with a reduction in total
mortality compared to other oral anti-hyperglycaemic
treatments.51 Metformin has been considered to in-
crease the risk of lactic acidosis and is contraindicated
in many chronic hypoxaemic conditions, such as
cardiovascular, renal, hepatic and pulmonary disease
as well as advancing age. Traditionally, metformin
has been stopped 48 hours before angiography or gen-
eral anaesthesia (approximately 90% of metformin is
eliminated via the kidneys in 24 h). Renal insufficiency
(GFR < 70 ml/min or serum creatinine >140 mmol/L)
results in tissue retention of biguanides with the poten-
tial for development of fatal lactic acidosis. Therefore,
metformin is contraindicated in patients with chronic
renal failure.
However in patients with normal renal function
a Cochrane review, evaluating the incidence of fatal
and nonfatal lactic acidosis for metformin treatment
and for placebo or other treatments, showed no cases
of fatal or nonfatal lactic acidosis in 47,846 patient-
years of metformin use or in 38,221 patients-years in
the non-metformin group.52 The true incidence of
metformin-associated lactic acidosis was 6.3 cases
587Diabetes Care for Patients with PADper 100,000 patient-years, and the upper limit for
the true incidence of lactic acidosis in the non-
metformin group was 7.8 cases per 100,000 patient-
years.52 There was no difference in lactate levels,
either as mean treatment levels or as a net change
from baseline, for metformin compared to placebo
or other non-biguanide therapies. Therefore metfor-
min use does not appear to be associated with an in-
creased risk of lactic acidosis, or with increased levels
of lactate, compared to other anti-hyperglycemic
treatments if prescribed under the study conditions.
Angiography and revascularization angioplasty
or bypass operation is often needed in patients
with PAD and diabetes. The use of contrast media
in patients receiving metformin should be carried
out with care. Contrast media can induce a reduction
in renal function, which occurs after the contrast
medium has reached the kidney, leading to reten-
tion of metformin that may induce lactic acidosis.
There is no conclusive evidence that the intravascu-
lar use of contrast media precipitates the metformin
induced lactic acidosis in patients with normal
serum creatinine (<130 mmol/L). The complication
has almost always been observed in patients with
non-insulin dependent diabetes with abnormal renal
function. Serum creatinine level should be measured
in all patients treated with metformin before intra-
vascular administration of contrast media. If serum
creatinine is normal, the radiological examination
can be performed and intake of metformin stopped
from the time of the study. Metformin should not be
resumed for 48 hours and should only be restarted
if renal function/serum creatinine remains within
the normal range.53 If renal function is abnormal,
metformin should be stopped and the contrast
study should be delayed for 48 hours. Patients
with abnormal renal function should be hydrated
before and after angiography. Recommendations
for patients on metformin therapy undergoing angio-
graphy and/or vascular surgery are summarised
in Table 2.
Peri-operative Diabetic Care
Strategies to improve operative results and long-term
prognosis of vascular surgery pose formidable practi-
cal challenges to scheduling of surgery. Pre-operative
assessment 2 weeks before scheduled surgery permits
evaluation of diabetic control and comorbidities and
the need to institute therapies to decrease operative
risk. Poor pre-operative glycaemic control is
associated with hyperglycaemia and increased insulin
requirements peri-operatively. An ideal marker ofpoor glycaemic control is yet to be defined but it is
good practice is to consult a diabetologist about inten-
sifying therapy if the value of plasma HbA1c exceeds
7%. Higher levels are associated with increased 30-day
mortality (OR 4.8, 95% CI 1.4e16.8) after vascular sur-
gery.54 Accumulating evidence shows the value of
peri-operative beta-blockade in reducing cardiac mor-
bidity and mortality associated with surgery in high
risk patients.55,56 There is a body of evidence to
support Institutional protocols advocating the use of
peri-operative beta blockade in patients with diabetes
undergoing high risk vascular surgery. However, level
1 evidence is lacking and a recent randomized trial of
patients with diabetes undergoing major non-cardiac
surgery failed to demonstrate a benefit with
Table 2. Perioperative care of a patient with diabetes undergoing
peripheral vascular surgery
Preoperatively þSchedule a preoperative visit for an anesthesia
consultation at least two weeks before planned
surgery. During this visit consider preoperative
interventions if:
HbA1c > 7%/Need of improvement of
diabetic control (diabetology consultation)
Ischemic heart or brain disese, renal insuffi-
ciency/ Institute beeta-blockade
Ischemic heart disease/Revascularization
(PMI or CABG) only if indicated independently
of the planned vascular surgey (cardiology
consultation)
þDiscontinue (last dose) of sulfonylureas 24 hours
and biguanides 48 hours before the scheduled
surgery
Perioperatively þNil by mouth 6 hours before anesthesia induction
þGlargine-insulins continued with the
prescribtion dose
þDiabetics need to be scheduled as a first case in
the morning
þArterial catheter for direct blood pressure
measurement and frequent blood samples
þBlood glucose between 5.0e8.0 mmol/l
(sampling interval 0.5e2 hours)
þInfuse glucose 5 g/hour as long as patient can
take per os
þShort acting insulins sc or iv
þRegional anesthetic techcniques preferable
þPONV*- prophylaxis with 5 HT3 receptor
antagonists
Postoperatively þBlood glucose between 5.0e10 mmol/l
(sampling interval 6 hours) in the ward and/or
intensive care in the euglycemic range (sampling
interval 1e2 hours)
þNormal prescribed insulin regimen in the
patients taking orally. If not, glucose-insulin-
potassium (GIK) infusion iv on the ward and
separate glucose and insulin-infusions in intensive
care.
HbA1c¼ hemoglobin A1c, PMI¼ percutaneous myocardial inter-
vention, CABG¼ coronary artery bypass, NPO¼ nothing per os,
PONV¼ perioperative nausea and vomiting, ICU¼ internal care
unit.
* PONV postoperative nausea and vomiting.Eur J Vasc Endovasc Surg Vol 33, May 2007
588 M. Heikkinen et al.metoprolol.57 Interventional coronary procedures be-
fore vascular surgery should be considered only if
they are indicated independently, despite the planned
surgery.58 Oral hypoglycemic agents may be associ-
ated with hypogycemia during anaesthesia and
surgery, and should be stopped before surgery.
Although discontinuation 24 hours before surgery
seems advisable, many institutional protocols usually
suggest withholding of metformin for 48 hours before
major surgery. This practice is based only on circum-
stantial evidence from case reports and observational
studies associating metformin with lactic acidosis.
Some authors suggest also that prior to surgical pro-
cedures under general anaesthesia, withdrawal of
metformin the evening before is safe in patients with
normal renal function.59
Insulin-dependent patients should be scheduled
as first cases in the morning. Peri-operative fast
will aggravate metabolic imbalances due to anaes-
thesia and surgery. Oral fluid restriction before an-
aesthesia induction has in been reduced to 2 hours
for many, but in those with diabetes restriction ofEur J Vasc Endovasc Surg Vol 33, May 2007all oral intake for 6 hours before surgery is still rec-
ommended because of the anticipated gastroparesis
as a result of autonomic neuropathy.60 Longer
periods without any intake force the use of intrave-
nous glucose and insulin, which can be challenging
in a ward setting. As a general rule regional anaes-
thesia should be preferred over general anaesthesia
because early institution of oral intake and restitu-
tion of the prevailing diabetes care is easier. Due
to the autonomic neuropathy in patients with long-
standing diabetes, patients are liable to haemody-
namic instability during anaesthesia.61 Therefore
invasive arterial blood pressure measurement and
extended haemodynamic monitoring often should
be instituted promptly to minimize haemodynamic
deterioration. Monitoring also is the most efficacious
renal protective strategy in patients with borderline
renal compromise and recent angiography. Although
n-acetylcysteine may counteract against the contrast
media-induced nephropathy it fails to have any pro-
tective effect in patients during abdominal aortic
surgery.62Table 3. Intravascular administration of contrast media and patients taking metformin or other biagunides
General þLow- or iso-osmolar contrast media should always be used.
þSerum creatinine level should be measured before the examination in every patients before the
administration of contrast media
þIf renal function is abnormal, alternative imaging techniques (MRI, CO2 angiography) should be
considered. If contrast media administration is seen necessary, patient should be hydrated, renal function
monitored and symptoms/signs for lactic acidosis (vomiting, somnolence, nausea, epigastric pain, anorexia,
hyperpnoea, lethargy, diarrhoea, thirst, lactic acidosis in blood test (pH< 7.25, lactic acid>5 mmol/l)
Elective examinations
Current recommendation Suggested new recommendation
Normal renal function þMetformin intake is stopped 48 hours prior to
examination in all patients taking metformin and
restarted 24 hours after the procedure if renal
function is normal. If creatinine level is elevated
after the examination, metformin is restarted
48 hours after the examination
þIntake of metformin should be stopped from the
time of study
þThe use of metformin can be restarted 48 hours after
intravascular administration of contrast media if the
postexamination creatinine is within normal range
Abnormal renal function
(Alternative imaging
techniques should be
considered)
þMetformin intake is stopped 48 hours prior to
examination in all patients taking metformin and
restarted 48 hours after the procedure if renal
function is unchanged
As the current recommendation
Emergency examinations
Current recommendation Suggested new recommendation
Normal renal function þIf urgent examination is seemed necessary,
metformin is stopped at the time of study.
þIntake of metformin should be stopped from the
time of study
þOtherwise, netformin intake is stopped
48 hours prior to examination in all patients
taking metformin
þThe use of metformin can be restarted 48 hours after
intravascular administration of contrast media if the
postexamination creatinine is within normal range
þMetformin is restarted 24 hours after
the procedure if renal function is normal
Abnormal renal function
(Alternative imaging
techniques should be
considered)
þMetformin should be stopped 48 hours
prior to examination if possible.
As the current recommendation
þIf urgent examination is seemed necessary,
metformin is stopped at the time of study
þMetformin is restarted 48 hours after the
procedure if renal function unchanged
589Diabetes Care for Patients with PADThe fasting patient does not tolerate the standard
morning insulin dose. An exception is newer long-
acting insulin analogue glargine, which can be admin-
istered for basal insulin coverage through-out the
surgical period. Usually it is advisable to resort to
short-acting insulins and dose them according to
point-of-care blood glucose analysis. If resumption
of oral intake is anticipated later on the day of surgery,
subcutaneous insulin administration and intravenous
glucose can be used. More extensive surgery requires
continuous insulin and glucose infusion. The goal
should be avoidance of hyperglycaemia, although
the studies that show benefits of this are from cardiac
surgery. During coronary bypass surgery patients
with tight glycaemic control had a lower incidence
of atrial fibrillation, fewer episodes of myocardial
ischemia, fewer wound infections and a survival
advantage 2 years after surgery.63
In the intensive care unit, maintenance of euglycae-
mia is associated with improved survival both on the
unit and in-hospital.64 These results can be extrapo-
lated to patients undergoing vascular surgery. Poor
glycaemic control has been associated with the devel-
opment of renal insufficiency, infectious complications
and poor outcome i.e. death, amputation and graft
occlusion.65 Despite this evidence, the optimal blood
glucose target window remains to be determined.
Euglycemia may not be a safe or rational goal during
anaesthesia due to the likelihood of hypoglycaemic
episodes. In the ’’classic’’ study the incidence of hypo-
glycaemia (glucose< 2.2 mmol/l) was 39% in the
euglycemic group versus 6% in the group with moder-
ate hyperglycemia.64 Hypoglycaemic episodes can be
masked by anaesthesia and sedation and point of
care measurements may provide erroneous glucose
estimates, up to þ/ 2 mol/l from the true value.66
Deep infections after coronary artery bypass
increased only after blood glucose values exceeded
12 mmol/l.67 Finney et al. were able to show that
the predicted threshold glucose range for mortality
benefit in intensive care was in the range 8.0e
11.1 mmol/L.68 Therefore we believe that our target
window of 5.0e8.0 mmol/l for vascular surgery is
appropriate. Conventional sliding scale insulin infu-
sion has been challenged by the hyperinsulinaemic
normoglycaemic clamp technique, where insulin is
administered at a constant rate and blood glucose
controlled by varying the rate of glucose adminis-
tration. This method has been shown to prevent
the hyperglycaemia and increased insulin require-
ments after surgery.69 Recommendations for peri-
operative management of patients with diabetes
undergoing major vascular surgery are summarised
in Table 3.Finally the transition of intensive insulin therapy to
a more conventional therapy applicable to ward con-
ditions is challenging. Separate intravenous insulin
and glucose administration routes are not safe on
the ward. Therefore prolongation of stay in intensive
care or recovery may be indicated to provide the
benefits of tight glucose control to vascular surgery
patients.
References
1 MAYOR S. Diabetes affects nearly 6% of the world’s adults. BMJ
2006;9:1191.
2 MARSHALL SM, FLYVBJERG A. Prevention and early detection of
vascular complications of diabetes. BMJ 2006;2:475e480.
3 Finnish Diabetes Association.Developement program for prevention
of type 2 diabetes. Population Strategy 2003e2010. Tampere:
Hermes Oy, 2003.
4 JONSSON B. CODE-2 Advisory Board. Revealing the cost of Type II
diabetes in Europe. Diabetologia 2002;45:S5eS12.
5 KULZER B. Diabetes mellitus: how important is it to measure the
qualityof life?DtschMedWochenschr2006;131(Suppl. 8):S259eS263.
6 ADLERBERTH AM, ROSENGREN A, WILHELMSEN L. Diabetes and long-
term risk of mortality from coronary and other causes in middle-
aged Swedish men. A general population study. Diabetes Care
1998;21:539e545.
7 MUNTNER P, HE J, ASTOR BC, FOLSOM AR, CORESH J. Traditional and
nontraditional risk factors predict coronary heart disease in
chronic kidney disease: results from the atherosclerosis risk in
communities study. J Am Soc Nephrol 2005;16:529e538.
8 EASON SL, PETERSEN NJ, SUAREZ-ALMAZOR M, DAVIS B, COLLINS TC.
Diabetes mellitus, smoking, and the risk for asymptomatic
peripheral arterial disease: whom should we screen? J Am Board
Fam Pract 2005;18:355e361.
9 NORGREN L, HIATT WR, DORMANDY JA, NEHLER M, HARRIS KA,
FOWKES FGR on behalf of the TASC II Working Group. Inter-
Society Consensus for the Management of Peripheral Arterial
Disease. Eur J Vasc Endovasc Surg 2007;33(Suppl. I):S1eS75.
10 NATHAN DM, LACHIN J, CLEARY P, ORCHARD T, BRILLON DJ,
BACKLUND JY, et al. Diabetes Control and Complications Trial,
Epidemiology of Diabetes Interventions and Complications
Research Group. Intensive diabetes therapy and carotid intima-
media thickness in type 1 diabetes mellitus. N Engl J Med 2003;5:
2294e2303.
11 KALLIO M, FORSBLOM C, GROOP PH, GROOP L, LEPA¨NTALO M. Devel-
opment of new peripheral arterial occlusive disease in patients
with type 2 diabetes during amean follow-up of 11 years.Diabetes
Care 2003;26:1241e1245.
12 SELVIN E, MARINOPOULOS S, BERKENBLIT G, RAMI T, BRANCATI FL,
POWE NR et al. Meta-analysis: glycosylated hemoglobin and
CVD disease in diabetes mellitus. Ann Intern Med 2004;21:
421e431.
13 MUNTNER P, WILDMAN RP, REYNOLDS K, DESALVO KB, CHEN J,
FONSECA V. Relationship between HbA1c level and peripheral
arterial disease. Diabetes Care 2005;28:1981e1987.
14 ESKELINEN E, LEPA¨NTALO M, HIETALA EM, SELL H, KAUPPILA L,
MA¨ENPA¨A¨ I et al. Lower limb amputations in Southern Finland
in 2000 and trends up to 2001. Eur J Vasc Endovasc Surg 2004;
27:193e200.
15 OYIBO SO, JUDE EB, VOYATZOGLOU D, BOULTON AJM. Clinical char-
acteristics of patients with diabetic foot problems: changing pat-
terns of foot ulcer presentation. Pract Diabetes Int 2002;19:10e12.
16 JUDE EB, BOULTON AJM. Diabetic foot. In: BEARD J, GAWES P, eds.
Vascular and Endovascular Surgery. 3rd edn. Elsevier Saunders,
2006:118e137.
17 VIRKKUNEN J, HEIKKINEN M, LEPA¨NTALO M, METSA¨NOJA R,
SALENIUS JP, Finnvasc Study Group. Diabetes as an independentEur J Vasc Endovasc Surg Vol 33, May 2007
590 M. Heikkinen et al.risk factor for early postoperative complications in critical limb
ischemia. J Vasc Surg 2004;40:761e767.
18 CHUNG J, BARTELSON BB, HIATT WR, PEYTON BD, MCLAFFERTY RB,
HOPLEY CW et al. Wound healing and functional outcomes after
infrainguinal bypass with reversed saphenous vein for critical
limb ischemia. J Vasc Surg 2006;43:1183e1190.
19 HOUBEN AJ, NIEUWENHUIJZEN KRUSEMAN AC, BOUHOUCH E,
SLAAF DW, SCHAPER NC. Peripheral macro- and microcirculation
in short-term insulin-dependent diabetes mellitus: the role of
prostaglandins in early haemodynamic changes. Eur J Clin Invest
1993;23:662e667.
20 FLYNN MD, O’BRIEN IA, CORRALL RJ. The prevalence of autonomic
and peripheral neuropathy in insulin-treated diabetic subjects.
Diabet Med 1995;12:310e313.
21 FOWLER B, JAMROZIK K, NORMAN P, ALLEN Y. Prevalence of periph-
eral arterial disease: persistence of excess risk in former smokers.
Aust N Z J Public Health 2002;26:219e224.
22 GUERCI B, BOHME P, KEARNEY-SCHWARTZ A, ZANNAD F, DROUIN P.
Endothelial dysfunction and type 2 diabetes. Part 2: altered en-
dothelial function and the effects of treatments in type 2 diabetes
mellitus. Diabetes Metab 2001;27(4 Pt 1):436e447.
23 The Diabetes Control and Complications Trial Research Group.
The effect of intensive treatment of diabetes on the development
and progression of long-term complications in insulin-
dependent diabetes mellitus. N Engl J Med 1993;30:977e986.
24 UK Prospective Diabetes Study (UKPDS) Group. Intensive
blood-glucose control with sulphonylureas or insulin com-
pared with conventional treatment and risk of complications
in patients with type 2 diabetes (UKPDS 33). Lancet 1998;12:
837e853.
25 GAEDE P, VEDEL P, LARSEN N, JENSEN GV, PARVING HH, PEDERSEN O.
Multifactorial intervention and cardiovascular disease in
patients with type 2 diabetes. N Engl J Med 2003;30:383e393.
26 CLEARY PA, ORCHARD TJ, GENUTH S, WONG ND, DETRANO R,
BACKLUND JY, et al. DCCT/EDIC Research Group. The effect of
intensive glycemic treatment on coronary artery calcification in
type 1 diabetic participants of the Diabetes Control and Compli-
cations Trial/Epidemiology of Diabetes Interventions and Com-
plications (DCCT/EDIC). Study. Diabetes 2006;55:3556e3565.
27 STRATTON IM, ADLER AI, NEIL HA, MATTHEWS DR, MANLEY SE,
CULL CA et al. Association of glycaemia with macrovascular
and microvascular complications of type 2 diabetes (UKPDS
35): prospective observational study. BMJ 2000;12:405e412.
28 BAYNES JW, THORPE SR. Role of oxidative stress in diabetic compli-
cations: a new perspective on an old paradigm. Diabetes 1999;48:
1e9.
29 Hypertension in Diabetes Study (HDS): I. Prevalence of hyper-
tension in newly presenting type 2 dia-betic patients and the
association with risk factors for cardiovascular and diabetic
complications. J Hypertens 1993;11:309e317.
30 STRIPPOLI GF, CRAIG M, CRAIG JC. Antihypertensive agents for pre-
venting diabetic kidney disease. Cochrane Database Syst Rev 2005;
19: CD004136.
31 DOMANSKI M, MITCHELL G, PFEFFER M, NEATON JD, NORMAN J,
SVENDSEN K, et al. MRFIT Research Group. Pulse pressure and
cardiovascular disease-related mortality: follow-up study of
the Multiple Risk Factor Intervention Trial (MRFIT). JAMA
2002;22-29:2677e2683.
32 UK Prospective Diabetes Study Group. Tight blood pressure
control and risk of macrovascular and microvascular complica-
tions in type 2 diabetes: UKPDS 38. BMJ 1998;12:703e713.
33 MORGENSEN CE. New treatment guidelines for a patient with
diabetes and hypertension. J Hypertens Suppl 2003;21:S25eS30.
34 Heart Protection Study Collaborative Group. MRC/BHF Heart
Protection Study of cholesterol lowering with simvastatin in
20,536 high-risk individuals: a randomised placebo-controlled
trial. Lancet 2002;6:7e22.
35 COLHOUN HM, BETTERIDGE DJ, DURRINGTON PN, HITMAN GA,
NEIL HA, LIVINGSTONE SJ et al. CARDS investigators. Primary
prevention of cardiovascular disease with atorvastatin in type
2 diabetes in the Collaborative Atorvastatin Diabetes StudyEur J Vasc Endovasc Surg Vol 33, May 2007(CARDS): multicentre randomised placebo-controlled trial.
Lancet 2004;21-27:685e696.
36 COSTA J, BORGES M, DAVID C, VAZ CARNEIRO A. Efficacy of lipid
lowering drug treatment for diabetic and non-diabetic patients:
meta-analysis of randomised controlled trials. BMJ 2006;13:
1115e1124.
37 WINELL K, NIEMI M, LEPA¨NTALO M. The National Hospital
Discharge Register data on lower limb Amputations. Eur J Vasc
Endovasc Surg 2006;32:66e70.
38 GILIS-JANUSZEWSKA A, SZURKOWSKA M, SZYBINSKI K, GLAB G,
SZYBINSKI Z, SPODARYK K et al. The efficacy of non-pharmacological
intervention in obese patients with newly diagnosed diabetes
mellitus type II. Pol Arch Med Wewn 2001;106:853e860.
39 TUOMILEHTO J, LINDSTROM J, ERIKSSON JG, VALLE TT, HAMALAINEN H,
ILANNE-PARIKKA P et al. Finnish Diabetes Prevention Study Group.
Prevention of type 2 diabetes mellitus by changes in lifestyle
among subjects with impaired glucose tolerance. N Engl J Med
2001;3:1343e1350.
40 LINDSTROM J, ILANNE-PARIKKA P, PELTONEN M, AUNOLA S,
ERIKSSON JG, HEMIO K et al. Finnish Diabetes Prevention Study
Group. Sustained reduction in the incidence of type 2 diabetes
by lifestyle intervention: follow-up of the Finnish Diabetes
Prevention Study. Lancet 2006;11:1673e1679.
41 WATALA C, GOLANSKI J, PLUTA J, BONCLER M, ROZALSKI M, LUZAK B
et al. Reduced sensitivity of platelets from type 2 diabetic
patients to acetylsalicylic acid (aspirin)-its relation to meta-bolic
control. Thromb Res 2004;113:101e113.
42 SACCO M, PELLEGRINI F, RONCAGLIONI MC, AVANZINI F, TOGNONI G,
NICOLUCCI A, PPP Collaborative Group. Primary prevention of
cardiovascular events with low-dose aspirin and vitamin E in
type 2 diabetic pa-tients: results of the Primary Prevention Pro-
ject (PPP) trial. Diabetes Care 2003;26:3264e3272.
43 MEADE TW, BRENNAN PJ. Determination of who may derive most
benefit from aspirin in primary prevention: subgroup results
from a randomised controlled trial. BMJ 2000;321:13e17.
44 WATALA C, PLUTA J, GOLANSKI J, ROZALSKI M, CZYZ M,
TROJANOWSKI Z et al. Increased protein glycation in diabetes
mellitus is associated with decreased aspirin-mediated protein
acetylation and reduced sensitivity of blood platelets to aspirin.
J Mol Med 2005;83:148e158.
45 ROFFI M, TOPOL EJ. Percutaneous coronary intervention in dia-
betic patients with non-ST-segment eleva-tion acute coronary
syndromes. Eur Heart J 2004;25:190e198.
46 FERREIRA IA, MOCKING AI, FEIJGE MA, FERREIRA IA, MOCKING AI,
FEIJGE MA et al. Platelet inhibition by insulin is absent in type 2
diabetes mellitus. Arterioscler Thromb Vasc Biol 2006;26:417e422.
47 CAPRIE steering committee. A randomized, blinded, trial of
clopidogrel versus aspirin in patients at risk of ischemic events
(CAPRIE). Lancet 1996;348:1329e1339.
48 CURE trial investigators. Effects of clopidogrel in addition to
aspirin in patients with acute coronary syndromes without
ST-segment elevation. N Engl J Med 2001;345:494e502.
49 ANGIOLILLO DJ, FERNANDEZ-ORTIZ A, BERNARDO E, RAMIREZ C,
SABATE M, JIMENEZ-QUEVEDO P et al. Platelet function profiles in
patients with type 2 diabetes and coronary artery disease on
combined aspirin and clopido-grel treatment. Diabetes 2005;54:
2430e2435.
50 LEPA¨NTALO A, VIRTANEN KS, HEIKKILA J, WARTIOVAARA U, LASSILA R.
Limited early antiplatelet effect of 300 mg clopidogrel in patients
with aspirin therapy undergoing percutaneous coronary inter-
ventions. Eur Heart J 2004;25:476e483.
51 UK Prospective Diabetes Study (UKPDS) Group. Effect of inten-
sive blood-glucose control with metformin on complications in
overweight patients with type 2 diabetes (UKPDS 34). Lancet
1998;12:854e865.
52 SALPETER S, GREYBER E, PASTERNAK G, SALPETER E. Risk of fatal and
nonfatal lactic acidosis with met-formin use in type 2 diabetes
mellitus. Cochrane Database Syst Rev 2003;(2). CD002967.
53 THOMSEN HS, MORCOS SK. Contrast media and the kidney:
European Society of Urogenital Radiology (ESUR) guidelines.
Br J Radiol 2003;76:513e518.
591Diabetes Care for Patients with PAD54 O’SULLIVAN CJ, HYNES N, MAHENDRAN B, ANDREWS EJ, AVALOS G,
TAWFIK S et al. Haemoglobin A1c (HbA1C) in non-diabetic and
diabetic vascular patients. Is HbA1C an independent risk factor
and predictor of adverse outcome? Eur J Vasc Endovasc Surg 2006;
32:188e197.
55 MAGGIO PM, TAHERI PA. Perioperative issues: myocardial ische-
mia and protectionebeta-blockade. Surg Clin North Am 2005;
85:1091e1102.
56 POLDERMANS D, BOERSMA E, BAX JJ, THOMSON IR, VAN DE VEN LL,
BLANKENSTEIJN JD et al. The effect of bisoprolol on perioperative
mortality and myocardial infarction in high-risk patients under-
going vascular surgery. Dutch Echocardiographic Car-diac Risk
Evaluation Applying Stress Echocardiography Study Group.
N Engl J Med 1999;9:1789e1794.
57 JUUL AB, WETTERSLEV J, GLUUD C, KOFOED-ENEVOLDSEN A, JENSEN G,
CALLESEN T, et al. DIPOM Trial Group. Effect of perioperative
beta blockade in patients with diabetes undergoing major non-
cardiac surgery: randomised placebo controlled, blinded multi-
centre trial. BMJ 2006;24:1482.
58 KERTAI MD, BAX JJ, KLEIN J, POLDERMANS D. Is there any reason to
withhold beta blockers from high-risk patients with coronary
artery disease during surgery? Anesthesiology 2004;100:4e7.
59 HOLSTEIN A, EGBERTS EH. Traditional contraindications to the use
of metformin e more harmful than beneficial? Dtsch Med
Wochenschr 2006;20:105e110.
60 SOREIDE E, ERIKSSON LI, HIRLEKAR G, ERIKSSON H, HENNEBERG SW,
SANDIN R, et al. (Guidelines, Clinical Practice Committee Scandi-
navian Society of Anaesthesiology and Intensive Care Medicine).
Pre-operative fasting guidelines: an update. Acta Anaesthesiol
Scand 2005;49:1041e1047.
61 JERMENDY G. Clinical consequences of cardiovascular autonomic
neuropathy in diabetic patients. Acta Diabetol 2003;40(Suppl. 2):
S370eS374.
62 HYNNINEN MS, NIEMI TT, POYHIA R, RAININKO EI, SALMENPERA MT,
LEPANTALO MJ et al. N-acetylcysteine for the prevention of kidneyinjury in abdominal aortic surgery: a randomized, double-blind,
placebo-controlled trial. Anesth Analg 2006;102:1638e1645.
63 LAZAR HL, CHIPKIN SR, FITZGERALD CA, BAO Y, CABRAL H,
APSTEIN CS. Tight glycemic control in diabetic coronary artery
bypass graft patients improves perioperative outcomes and
decreases recurrent ischemic events. Circulation 2004;30:1497e1502.
64 VAN DEN BERGHE G, WOUTERS P, WEEKERS F, VERWAEST C,
BRUYNINCKX F, SCHETZ M et al. Intensive insulin therapy in the
critically ill patients. N Engl J Med 2001;8:1359e1367.
65 MALMSTEDT J, WAHLBERG E, JORNESKOG G, SWEDENBORG J. Influence
of perioperative blood glucose levels on outcome after infrain-
guinal bypass surgery in patients with diabetes. Br J Surg 2006;
93:1360e1367.
66 KANJI S, BUFFIE J, HUTTON B, BUNTING PS, SINGH A, MCDONALD K
et al. Reliability of point-of-care testing for glucose measurement
in critically ill adults. Crit Care Med 2005;33:2778e2785.
67 FURNARY AP, WU Y, BOOKIN SO. Effect of hyperglycemia and con-
tinuous intravenous insulin infusions on outcomes of cardiac
surgical procedures: the Portland Diabetic Project. Endocr Pract
2004;10(Suppl. 2):21e33.
68 FINNEY SJ, ZEKVELD C, ELIA A, EVANS TW. Glucose control and
mortality in critically ill patients. JAMA 2003;15:2041e2047.
69 CARVALHO G, MOORE A, QIZILBASH B, LACHAPELLE K, SCHRICKER T.
Maintenance of normoglycemia during cardiac surgery. Anesth
Analg 2004;99:319e324.
70 DE BACKER G, AMBROSIONI E, BORCH-JOHNSEN K, BROTONS C,
CIFKOVA R, DALLONGVILLE J et al. Third Joint Task Force of the
European and other Societes. European Guidelines on Cardio-
vascular Disease Prevention. Eur J Cardiovasc Preven Rehab
2003;10(S1):S1eS78.
71 American Diabetes Association. Standards of Medical Care in
Diabetes 2007. Diabetes Care 2007;30(S1):S4eS41.
Accepted 30 January 2007
Available online 26 March 2007Eur J Vasc Endovasc Surg Vol 33, May 2007
